Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Creative Planning

Creative Planning reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,555 shares of the company’s stock after selling 2,490 shares during the period. Creative Planning’s holdings in Amneal Pharmaceuticals were worth $138,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMRX. Hennessy Advisors Inc. acquired a new position in shares of Amneal Pharmaceuticals in the second quarter worth $8,818,000. Rubric Capital Management LP lifted its holdings in Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after purchasing an additional 1,179,830 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after purchasing an additional 710,598 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after purchasing an additional 641,405 shares during the last quarter. Finally, BlackBarn Capital Partners LP grew its holdings in shares of Amneal Pharmaceuticals by 41.5% during the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after buying an additional 586,703 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $9.25 on Wednesday. Amneal Pharmaceuticals, Inc. has a one year low of $4.15 and a one year high of $9.48. The stock has a 50-day moving average price of $8.54 and a 200 day moving average price of $7.59. The company has a market capitalization of $2.86 billion, a P/E ratio of -13.53 and a beta of 1.17.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of analyst reports. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday. Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. Finally, Piper Sandler increased their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.